An update to my column in Tuesday's paper about the mix of messages emerging from several of the region's life-sciences firms:

A spokeswoman for Takeda Pharmaceuticals U.S.A. Inc. said the sale price for generic drugs business that it will sell to Caraco Pharmaceutical Laboratories Ltd. is $65 million. Takeda will keep the gout drug Colcrys, which it said generated net sales of $155 million during the three months ended Sept. 30.

Takeda acquired Colcrys and the other generics when it acquired Philadelphia's URL Pharma Inc. in June for $800 million.

When the transaction between Takeda and Caraco closes within 60 days, the operations and the nearly 500 employees that comprise URL's two Philadelphia locations will transfer to Caraco, said Elissa J. Johnsen, of Takeda.

Takeda intends to move production of Colcrys to a non-U.S. facility, she said.

Detroit-based Caraco is a unit of Sun Pharmaceutical Industries Ltd., of Mumbai, India.

Here is a link to the print version of that column.